Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
08/2005
08/11/2005US20050176709 Selective NPY (Y5) antagonists
08/11/2005US20050176699 Benzodiazepine derivatives, preparation thereof and use thereof
08/11/2005US20050176678 Compounds and method for coating surfaces in a haemocompatibe manner
08/11/2005US20050176143 Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
08/11/2005US20050176142 Mammalian megakaryocyte progenitor cell
08/11/2005US20050176137 Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
08/11/2005US20050176083 Blood protein fusion comprising serine-protease (SP) domain for use in treatment of thrombosis a nd blood coagulation disorders
08/11/2005US20050175620 Multivalent platform molecules comprising high molecular weight polyethylene oxide
08/11/2005DE102004002351A1 New RNA aptamers specific for lipopolysaccharide-binding protein, useful for diagnosis and treatment of sepsis, inhibit the lipopolysaccharide-induced signaling cascade
08/11/2005CA2554911A1 Urea derivatives
08/10/2005EP1561760A2 Low molecular weight heparin salt with thriethanolamine
08/10/2005EP1561757A1 Modified factor VIII
08/10/2005EP1560591A2 Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
08/10/2005EP1560589A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
08/10/2005EP1357936A4 BIOCATALYTIC AND BIOMIMETIC GENERATION OF NITRIC OXIDE i IN SITU /i AT SUBSTRATE/BLOOD INTERFACES
08/10/2005EP1345946B1 Macroheterocylic compounds useful as kinase inhibitors
08/10/2005EP1339679B1 3-arylindole derivatives and their use as cb2 receptor agonists
08/10/2005EP1301207B1 Compositions for treating bacterial infections, containing an oxazolidinone compound, sulbactam and and ampicillin
08/10/2005EP0837883B1 Method of solubilizing, purifying, and refolding protein
08/10/2005EP0833622B1 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
08/10/2005CN1653059A Macrocyclic compounds useful as pharmaceuticals
08/10/2005CN1653055A Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same
08/10/2005CN1653046A 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
08/10/2005CN1653044A Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
08/10/2005CN1653036A Amino acids with affinity for the alpha-2-delta-protein
08/10/2005CN1652843A Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor
08/10/2005CN1652842A 3'- (2z)- 1-(3, 4-dimethylphenyl)-1, 5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1, 1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
08/10/2005CN1652812A Combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
08/10/2005CN1652811A A combination product comprising melagatran and an anti-arrhythmic oxabispidenes
08/10/2005CN1652810A Immunosuppressant compounds, methods and uses related thereto
08/10/2005CN1652808A Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic
08/10/2005CN1652802A Methods of treating necrotizing enterocolitis
08/10/2005CN1652786A Fluorinated 4-azasteroid derivatives as androgen receptor modulators
08/10/2005CN1652782A Nicotinamide derivatives useful as PDE4 inhibitors
08/10/2005CN1652779A Treatment of chemokine mediated diseases
08/10/2005CN1652777A Combination of organic compounds
08/10/2005CN1652774A Use of valsartan or its metabolite to inhibit platelet aggregation
08/10/2005CN1651470A Low molecular weight heparin triethanolamine salt usable as local delivery antithrombotic treating agent, preparing process and use thereof
08/10/2005CN1651466A Sulphatization derivative of polysaccharide, its preparation method and use
08/10/2005CN1651431A Inhibitors of alpha L beta 2 mediated cell adhesion
08/10/2005CN1651087A Combination of organic compounds
08/10/2005CN1651085A Compound aspirin tading kind medicinal preparation and its application
08/10/2005CN1651079A Shu xue tong (blood coursing free flowing) freeze dried powder snjection agent and its preparation method
08/10/2005CN1651071A CD154 blockade therapy for therapeutic protein inhibitor syndrome
08/10/2005CN1651057A Cinnamon poria capsule and its preparation process
08/10/2005CN1651042A Compound aspirin red yeast extract medicinal preparation and its application
08/10/2005CN1651033A Chinese medicinal composition for treating gynecopathy
08/10/2005CN1651019A Four ingredient soft capsule and its preparation process
08/10/2005CN1650978A Application of ligusticum oil in preparation of medicine for treating cerebral thrombosis
08/10/2005CN1650975A Preparation method of compound peach blossom deea tortoise life nourishing agent
08/10/2005CN1650972A Glow release micro pill containing gingko leaf extract and its preparation method
08/10/2005CN1650936A Water expelling swell dispersing pill
08/10/2005CN1650881A Erigeron breviscapus medicinal preparation and its preparation method
08/10/2005CN1214031C Hydropyridine deriv. acid addition salts
08/10/2005CN1214026C Indol-3-yl derivatives
08/10/2005CN1214017C 四唑衍生物 Tetrazole derivatives
08/09/2005US6927234 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
08/09/2005US6927231 and stress-related degenerative processes associated with aging or diseases such as cancer, neurodegenerative disease or dysregulation of redox-regulated physiological processes, indicated by prooxidative shift in plasma thiol/disulfide redox state
08/09/2005US6927230 Triazole derivatives
08/09/2005US6927228 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation
08/09/2005US6927222 Compounds
08/09/2005US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents
08/09/2005US6927209 5-thio-β-D-xylopryanoside derivatives, preparation, method, pharmaceutical compositions containing them and their therapeutic use
08/09/2005US6926898 Albumin fusion proteins
08/09/2005US6926884 GPIb-lipid bond construct and use thereof
08/09/2005CA2189705C Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
08/09/2005CA2095659C Heteroatoms-containing tricyclic compounds
08/04/2005WO2005070923A1 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
08/04/2005WO2005069717A2 The use os anti-rh antibodies for treating acute thrombocytopenia associated with dengue hemorrhagic fever, hepatitis c and other microbial infections
08/04/2005WO2005011648A3 Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems
08/04/2005US20050171345 Pteridine compounds for the treatment of psoriasis
08/04/2005US20050171186 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171123 Quinazoline derivatives as medicaments
08/04/2005US20050171103 Benzamide derivatives useful as histone deacetylase inhibitors
08/04/2005US20050171102 Semicarbazide derivatives for combating thromboembolic diseases
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171087 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171001 Hemostatic compositions and devices
08/04/2005US20050170504 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
08/04/2005US20050169983 Chewable soft capsule
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005CA2554332A1 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
08/04/2005CA2553714A1 Support accumulating in injured part in vascular channel
08/03/2005EP1559438A1 Hemostatic compositions and devices
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1559421A1 Blood fluidity improving agent
08/03/2005EP1559374A1 Cyanine dyes
08/03/2005EP1558606A2 Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
08/03/2005EP1558598A1 Triazole compounds for the treatment of dysmenorrhoea
08/03/2005EP1558080A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
1 ... 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 ... 671